



ASX ANNOUNCEMENT

28 NOVEMBER 2025

Company update – board changes, shareholder feedback & support

Sydney, Australia, 28 November 2025: Chimeric Therapeutics Limited (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to update shareholders following its Annual General Meeting (AGM) held on 25 November 2025.

Chimeric notes substantial feedback received from its shareholders, including from its major shareholder, on a range of matters. The Board and Management have taken this feedback with significant consideration and where appropriate will review the matters raised.

In recent months, Chimeric commenced planning for a refresh of its Board of Directors and will now prioritise this, including the appointment of a new Chairperson. As part of this, the US Family Office and major shareholder of the Company will nominate a Non-Executive Director for appointment to the Board, indicating its strong ongoing support of Chimeric. This and other changes to the Board will be announced once an appropriate process has been conducted and suitable, high-calibre candidates are appointed.

The outgoing Executive Chairman, Paul Hopper, has stated his ongoing support of Chimeric and its technologies as the Company’s second largest shareholder: “Having founded Chimeric in 2020 it has presented numerous opportunities, and I’m grateful for the dedicated team and shareholders. I’ll continue to retain my significant shareholding in the company and wish Rebecca and the team every success going forward.”

Chimeric’s lead CHM CDH17 Phase 1/2 trial is delivering continued disease control and tumour shrinkage in patients, with more data expected in Q1 CY26 as the trial reaches completion.

Chimeric’s CEO Dr Rebecca McQualter said: “CHM CDH17 is having a positive impact for patients and our clinical investigators remain highly encouraged by what they’re seeing. We look forward to reporting more on this including updates regarding duration over the coming months.

As we refresh the Board and bring our lead asset through to the end of Phase 1, we’re very optimistic about the future of the Company.”

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.



CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Acting Chairman Phillip Hains.

Contact

Investors

Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au